tional regulation by RAR and other nuclear receptors also occurs through antagonism or synergism with distinct families of transacting factors, including AP-1 (15-21; for review see reference 22) .
The influence of RAP, on lymphoid T cell differentiation and growth is suggested by the ability of RA to modulate the expression of the human and murine IL-2 genes, which encode a major T lymphocyte growth factor (23, 24) involved in the control of T cell development (25, 26) . The use of retinoids as therapeutic agents and the subsequent potential immunosuppression and influence on development underline the importance of elucidating their regulatory role in the IL-2 gene. The IL-2 promoter contains several control elements, which mainly require a variety of transacting factors activated by protein kinase C (PKC) and calcium-mediated signals (for reviews see references 27 and 28) . We have previously reported that one target of the RAp`-mediated inhibition of the PKCand calcium-mediated activation of the IL-2 enhancer is an octamer motif at a position -96 to -66 bp upstream of the start site (23) . This motif binds the inducible nuclear factor(s) OAP 4~ whose composition includes jun protein (29, 30) , as well as both Oct-l-and Oct-2-transacting factors (29, 31, 32) , which are, therefore, potential targets of RA-mediated regulation. Whereas Oct-1 is ubiquitous, Oct-2 has a more restricted pattern of cell distribution, being expressed in B cells and in some T cells (31, 32) . Furthermore, both transacting factors are regulated by stimuli that activate the IL-2 gene (29, 31, 32) . Specifically, Oct-2 levels are upregulated by antigen stimulation in some T cells (32) .
The presence of distinct Oct factors regulating cytokine gene expression suggests that they might be responsive to differential regulatory pathways. Indeed, distinct transcriptional requirements for Oct-1 and Oct-2 have been reported. Whereas Oct-1 is competent in enhancing transcription from snRNA promoters, it requires supplementation by auxiliary factors, which provide transcriptional activation domains (e.g., the herpes virus VP16 protein harbors a strong acidic transactivation domain) to activate mp`NA promoters (13, 33) . In contrast, Oct-2 harbors a strong COOH-terminal transcriptional activation domain for mp`NA promoters, which when replacing the Oct-1 COOH terminus, can provide transcriptional activation (13, 34) . The OAP 4~ complex may represent auxiliary factors required for Oct-1 function. However, the requirements of Oct-2 for the regulation of the IL-2 promoter remain to be elucidated.
In this study we have addressed the molecular events implicated in the Oct-2-dependent activation and P,A-induced downregulation of the octamer motif of the IL-2 enhancer. We show that the IL-2 octamer motif is a composite binding site for Oct-2 and afis-andjun-containing AP-1 complex, whose functional cooperation is required to fully enhance transcription. P,AP,cx is able to inhibit the formation of the AP-1-DNA complex in vitro, resulting in an interference with the Oct-2-dependent c/s-regulatory function of this AP-1 element. Therefore, the AP-1 element appears to be the main target for positive or negative regulatory signals that influence the IL-2 octamer motif, either through cooperation with Oct-2 or antagonism by RAP,.
Materials and Methods
Plasmid Constructs. The plasmid pIL2CAT contains the IL-2-flanking region from -575 to + 47 bp driving the chloramphenicol acetyltransferase (CAT) gene (35) . All reporter constructions based on the pBLCAT2 vector were prepared by use of a vector in which the AP-1 site in the plasmid backbone had been deleted, as previously described (17) . IL-2-OAP/OCT-tk-CAT was constructed by inserting four copies of the proximal (-96 to -66-bp) Ib2 octamer motif into either the pBIg2AT2 vector (36) (including the octamerless [-105-bp] thymidine kinase [tk] promoter driving the CAT gene) or the (-37-bp) tk-CAT vector (37), as previously described (23) . All of the plasmids containing mutated (m) or deleted (A) sequences of the ID2 octamer motif (described in Fig. 6 ) were prepared in the same way. Wild-type deletion mutants and chimeric forms of Oct-1 and Oct-2 cDNAs, cloned in pCG expression vector containing the human CMV promoter, were provided by Dr. W. Herr (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) (34) . pRcKSV-OCT2 was constructed by inserting the Oct-2 cDNA in the pRcRSV vector (Invitrogen, San Diego, CA). Expression vectors encoding hKARc~ and its mutant forms (A1-81 and A81-152) and RXR~x were provided by Dr. P. Chambon (Laboratoire de G6n&ique Mol&ulaire des Eucaryotes du CNKs, Strasbourg, France) and Dr. K. Evans (Howard Hughes Medical Institute) (19, 38) . The plasmid tk-TREp2-CAT contains the RAresponsive element driving the CAT gene through the tk promoter (39) . pAP-lcoll-tk-CAT contains five copies of the collagenase AP-1 site in front of the tk promoter (40) . JMneo (c-Jos expression vector), J~s-Bneo 0~s-B expression vector), their control vector pRAXneo, and expression vectors for c-jun and jun-B under the control of the Rous sarcoma virus (RSV) promoter (KSV c-jun and RSVjun-B) and their control vector pUC-RSV were as previously described (41) (42) (43) (44) . Thejun-D expression vector, containing jun-D cDNA under the control of the CMV promoter in the pCMV-1 vector, has been previously described (17) .
Cell Culture and DNA Transfection. The human Jurkat T cell lines (T-77 clone and a subclone partially resistant to RA) were cultured in RPMI 1640 medium supplemented with 10% FCS and antibiotics (50 IU/ml penicillin and 50 #g/ml streptomycin; Flow Laboratories, Ayrshire, Scotland). HeLa cells were grown in DMEM (Flow Laboratories) supplemented with 10% FCS and antibiotics as described above. Jurkat cells were treated with 30 ng/ml 12-O-tetradecanoyl-phorbol-D-acetate (TPA), 1/~g/ml A23187 or 2 #g/ml ionomycin (Sigma Chemical Co., St. Louis, MO), in the presence or absence of 1/~M RA (Sigma Chemical Co.).
Transfection of Jurkat cells were carried out either by the DEAE dextran method as previously described (23, 45) or by electroporation. In the latter case, phsmid DNA mixtures were, added to 107 Jurkat cells/ml medium without serum and antibiotics and electroporated in a gene pulser apparatus (Bio-Rad Laboratories, Richmond, CA) using 350 V and 960/iF capacitance, and then further cultured in complete growth medium. All cells were cotransfected with plasmid pCH110 (Pharmacia, Uppsala, Sweden) as an internal control for transfection ef~ciency. 24 h after transfection, cells were treated with the drugs indicated above. After a further 24 h, cells were harvested and protein extracts were prepared for the CAT and B-galactosidase assays, as previously described (23) . Data were quantified by autoradiography and liquid scintillation counting and normalized to the levels of B-galactosidase expression of cotrans-fected pCHll0 vector obtained from the same cell extract. The levels of transfected Oct proteins were monitored by gel retardation assays and Western blotting (by use of anti-Oct-1 and -Oct-2 antibodies, described in reference 46).
Nuclear Extracts. Nuclear extracts from Jurkat T cells were prepared by a modification of a previously described technique (47) . Cells were lysed by homogenization in 10 mM Hepes, pH 7.9, 10 mM KCI, 1.5 mM MgC12, I mM EDTA, 1 mM dithiothreitol, 1 mM PMSF, 10% glycerol, and 0.2% NP-40. Nuclei were centrifuged at 1,000 g and resuspended in two volumes of the abovedescribed solution. KC1 was added to a final concentration of 0.39 M, and nuclei were extracted at 4~ for I h and centrifuged at 100,000 g for 30 rain. The supematants were dialyzed against 20 mM Hepes, pH 7.9, 50 mM KC1, 1 mM PMSF, 1 mM DTT, and 20% glycerol, the debris removed by centrifugation, and stored at -80~ Nuclear extracts from HeLa cells were prepared by homogenizing cells in 10 mM Hepes, pH 7.9, 1.5 mM MgClz, 10 mM KC1, 0.5 mM PMSF, and 0.25 mM DTT. Nuclear fractions were extracted in 20 mM Hepes, pH 7.9, 20% glycerol, 0.42 M NaC1, 0.2 mM EDTA, 1.5 mM MgC12, 0.25 mM DTT, and 0.5 mM PMSF, dialyzed against 20 mM Hepes, pH 7.9, 50 mM KC1, 1 mM PMSF, 1 mM DTT, and 20% glycerol, and cell debris were removed by centrifugation.
In Vitro Translation. RNA Isopropyl-~-n-thiogalactopyranoside (IPTG; Sigma Chemical Co.) was added to final concentration 0.4 mM for 3 h to induce hRARot protein expression. Recombinant protein was then purified on resincharged columns (ProBond; Invitrogen) according to the manufacturer's recommendation. KAKor protein was verified by Western immunoblot analysis using anti-RARc~ primary antibody Ab9c~(hF) (provided by Dr. Chambon) diluted 1/1,500, as described (48).
Electrophoretic Mobility Shift Assay. 32p-labeled probes (0.4 ng, 50,000 cpm) were incubated with 10 #g nuclear extracts of Jurkat cells for 20 min at room temperature in 15 mM Hepes, pH 7.9, 2.5 mM MgC12, 2 mM DTT, 40 mM KC1, 4% glycerol, and 2-5 #g poly(dl-dC) (Sigma Chemical Co.). Anti-pan-fis (provided by Dr. M. Iadarola, National Institutes of Health, Bethesda, MD) (49) or anti-pan~/un antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA) were incubated with nuclear extracts for 1.5 h at 4~ after binding reactions, described above. In other experiments, 5 #g Jurkat nuclear extracts and/or 5/zl in vitro synthesized RAKcr and RXRoe or bacterially expressed KAKoe proteins were preincubated with 1 #g poly(dl-dC) in 10 mM Hepes, pH 7.9, 1 mM DTT, 2.5 mM MgC12, 10% glycerol, and a range of KC1 concentrations of 10, 40, and 100 mM for 15 rain on ice. After the addition of the KAR-responsive element of the RAR3 promoter (RARE3; 50) or OAP/OCT probe, the reaction mixtures were incubated for a further 25 min at room temperature. Anti-KAKc~ antibody Abgc~(hF) was incubated with the mixture for 15 min at 4~ after the binding reaction. All binding reactions were performed in a final volume of 20 #1. Protein-DNA complexes were separated from free probe by gel electrophoresis on 4% polyacrylamide gels in 0.25x TBE buffer (0.23 M Tris-borate, 1 mM EDTA, pH 8.0) at 150 V for 1.5 h at room temperature. Gels were dried and exposed to film (XAK-5; Eastman-Kodak, Rochester, NY) at -80"C. (Fig. 1) . Transactivation of the IL-2 enhancer and IL-2 octamer motif driving either the -105-bp tk or the -37-bp tk promoters was significantly stronger inJurkat cells transfected with Oct-2 expression vector after TPA and ionomycin treatment than that caused by endogenous Oct-1 in cells transfected with empty pCG vector (Fig. 1 A) . Accumulation of nuclear Oct-2-IL-2 octamer complex could be demonstrated in cells devoid of endogenous Oct-2 transfected with pCGOct2 vector, which encodes Oct-2 under the control of the CMV promoter ( Fig. 1 B) . The levels of this complex were augmented 10-20-fold by TPA and ionomycin treatment due to upregulation of the CMV promoter ( Fig. 1, A and B ). This drug-induced augmentation in Oct-2 levels alone would not appear to contribute to IL-2 octamer motif transactivation as CAT activity in the absence of TPA and ionomycin treatment was not significantly increased, despite similar levels ofintracellular Oct-2 protein (Fig. 1 , B and C; compare CAT activity and intracellular Oct-2 levels in cells transfected with 0.2/zg pCG-Oct-2 and treated with TPA/ionomycin to those transfected with 5/zg pCG-Oct-2 in the absence of TPA/ ionomycin). Similar results were obtained when Oct-2 expression vector driven by the KSV promoter (KSV-Oct2) was transfected into Jurkat cells, which was not significantly influenced by TPA/ionomycin (51; Fig. 1 A) . This would suggest a requirement for additional TPA/ionomycin-induced coregnlatory signals in Oct-2-mediated transactivation of octamer motif. TPA/ionomycin-induced Oct-2-dependent transactivation of both the intact IL-2 and the -96 to -66-bp IL-2 octamer motif was significantly inhibited by RA (Fig.  1 A) . As KA neither inhibited the activity of the CMV promoter, used to drive Oct-2 transcription (Fig. LA) , nor decreased the levels of Oct-2 protein resulting from transfection ( Fig. 1 D) , the inhibitory activity of KA likely resulted from interference with TPA/ionomycin-induced coregnlatory signals. These data suggest that the -96 to -66-bp IL-2 octamer motif is the focal point for both RA-mediated inactivation and the TPA/ionomycin-mediated cofactor requirement of Oct-2-dependent IL-2 transactivation.
Results

TPA and Calcium
Delineation of TPA/Ionornycin and RAR-responsive Domains in Oct-2.
To study the domains of the Oct-2 protein that are involved in TPA/ionomycin-induced transactivation and in the inhibitory activity of R.A, we cotransfected several constructs encoding Oct-2 and Oct-1 proteins carrying deletions in the NH2-or COOH-terminal regions or chimeric proteins together with the IL-2-OAP/OCT-(-10S)tk-CAT reporter (Fig. 2) . The levels of expression and integrity of these transfected wild-type mutant Oct-2 and Oct-2 proteins in each transfection were monitored by electrophoretic mobility shift assay (EMSA) of nuclear extracts from an aliquot of transfected cells. The complexes observed in EMSA were, in each case, consistent with expression of the fuU-length protein (Fig. 2 B) . The analysis of the transfected Oct-2 and Oct-1 proteins by EMSA showed that all mutant or chimeric proteins accumulated within the cells to comparable levels under basal conditions and after TPA/ionomycin or RA treatments (Fig. 2 B) . Oct protein levels analyzed by Western immunoblotting (with anti-Oct-2 and anti-Oct-1 antibodies; 46) corresponded to those determined by EMSA (data not shown). Similar TPA/ionomycin-induced transcriptional activation function and repression by RA was observed with Oct-2 proteins deleted of the proximal (94 amino acids, Oct-2AN1) or distal (adjacent glutamine-rich 62 amino acids, Oct-2AN2) NH2-terminal regions compared with the wild-type protein (Fig. 2 A) .
In contrast, deletion of the COOH terminus from residue 358 to the end (including a putative leucine zipper; Oct-2AC) decreased the transacting function (as evaluated by transfec- Figure 2 . Differential transcriptional activation of the octamer motif by wild-type, mutant, and chimeric Oct-1 and Oct-2 proteins. (A) Jurkat cells were cotransfected with 5 #g IL-2-OAP/OCT(-105)tk-CAT, 1 /zg RARot, and 1/~g of either the wild-type, mutant, or chimeric forms of the two Oct proteins, depicted on the left. Cells were treated with TPA and ionomycin and processed for CAT assay as described in Fig. 1 . CAT activities relative to untreated (basal) cells transfected with pCG vector are represented. Basal levels in pCG-transfected cells were 100 + 15 pmol/h/mg protein. CAT activities were normalized to the levels of transfected Oct proteins (considering the ratio between the protein levels and the CAT activity described in Fig. 1, A and B) and evaluated by EMSA of nuclear extracts from an aliquot of the cells. Results shown represent the average of three similar experiments (differing <20% from one another). (B) EMSA of the various wild-type and mutant Oct proteins observed in nuclear extracts from an aliquot of cells described in A. Assay and treatment conditions are as described in Fig. 1. tion over a range of 0.5-5/zg plasmid) (Fig. 2 A and data  not shown) . Likewise, the antagonistic activity of RA on Oct-2AC was almost lost (Fig. 2 A) . Surprisingly, transfection of the Oct-1 expression vector resulted in repression of the TPA/ionomycin-induced activation of the IL-2-OAP/OCTtk-CAT construct. Whereas the Oct-2 COOH terminus was required for enhancer transactivation, the inhibitory activity of Oct-1 also mapped to the COOH terminus, according to data recently reported by Annweiler et al. (52) for the B cell-specific enhancer stimulation. In fact, transfection of Oct-I/Oct-2 chimeric constructs indicated that whenever the Oct-1 COOH terminus was present in the fusion protein (Oct-2.1.1, Oct-1.2.1, Oct-2.2.1), the transactivation of the octamer CAT was repressed (Fig. 2) . Chimeric proteins containing the Oct-1 NH2 terminus with Oct-2 POU domain and COOH terminus (Oct-1.2.2) or Oct-1 POU domain and Oct-2 COOH terminus (Oct-l.L2) (transfected over a range of 0.5-5/~g plasmids) had comparably lower activity than Oct-2 NH2 terminus-containing proteins (Fig. 2) . They were, however, fully antagonized by RA. All of these data taken together show that an intact Oct-2 COOHterminus contributes to both the TPA/ionomycin-mediated activation and RA-induced inhibition, suggesting that TPA/caldum and RA signal through an overlapping pathway. To investigate this pathway, we studied the nuclear factors binding to the octamer motif.
Characterization of the Composite IL-2 0ctamer Motif: Presence of an AP-I Complex and Transcriptional Activation by fos
andjun. In addition to Oct-1 and Oct-2, a TPA/calciuminducible nuclear factor, previously termed OAP 4~ has been reported to bind to a region dosdy linked to the -96 to -66-bp IL-2 octamer-binding site (29) . The OAP binding site shares five out of seven nudeotides with a canonical AP-1 binding motif (Fig. 3 A) . The complex between the IL-2 octamer motif deleted from the Oct binding site (OAP/ AOCT) and nuclear factors extracted from TPA/ionomycinactivated Jurkat T cells was displaced by competition with an excess of either unlabeled collagenase AP-1 (Fig. 3 B, APt Coil) or the proximal (-160 to -139-bp) AP-1 site of the IL-2 promoter (not shown), which has been shown to bind jun and los proteins in activated T cells (21, 53 ). An unlabaled OAP/AOCT also competed for proteins from activated T cells that bind to an AP-1 site from the collagenase promoter ( Fig. 3 B, OAP) . Similar resuhs were observed with HeLa cell nuclear extracts as a source of AP-1 factor (Fig. 3 B) .
We also observed that antibodies against both los andjun proteins were able to bind to the complex formed by nuclear factors (from both Jurkat and HeLa cells) and the OAP/AOCT sequence motif, whereas an unrelated antibody was uneffectire ( Fig. 3 C and data not shown) . This result suggests that the protein complex that binds to the OAP/AOCT sequence containsfis andjun family members, which are components of AP-1. The OAP/AOCT sequence not only binds an AP-1 factor, but its c/s-regulatory function is also activated byjun andjSs. to be constitutively expressed inJurkat cells (54) . No significant increase in CAT activity was observed whenjun andJbs expression vectors were transfected in the absence of the Oct-2 vector (Fig. 4, pCG) .
The OAP c/s.Element Slmergizes with the Oct-20ctamer Complex and is Negatively Regulated by RAR.
The ability olios andjun to synergize with Oct-2 in enhancing the IL-2 octamer motif suggests that both elements may be required to drive transcription. To address this point, we introduced mutations or deletions in either or both OAP-and OCT-binding sites and tested their c/s-regulatory activity on a heterologous tk promoter. We first studied the binding specificity of these sequences versus OAP, Oct-l, and Oct-2 proteins by testing their ability to compete for binding to radiolabeled OAP/OCT or OAP/AOCT probes. Oligonucleotides carrying substitution mutations or a deletion of the OAP binding site (mOAP/OCT and AOAP/OCT, respectively) competed, as well as the wild-type OAP/OCT motif for in vitro translated Oct-2 ( Fig. 5 A, lanes 4-6) or endogenous Oct-1 ( Fig.   5 B, lanes 2, 4, and 5 ), but they did not bind the OAP factors (Fig. 5 B, lanes 4, 5, 14, and 15) . Mutations or deletions of the octamer-binding sequence (OAP/mOCT and OAP/AOCT, respectively) abolished the DNA-binding ability of Oct-2 and Oct-1 (Fig. 5 A, lanes 7 and 8 and Fig. 5 B, lane 3 ), but they still allowed binding of the OAP factors (Fig. 5 B, lanes   3, 12, and 13 ). An analysis of the functional activity of the mutated c/s-regulatory motifs indicated that four copies of the double-mutated OAP/OCT element (m(OAP/OCT)-tk-CAT), OAP/mOCT (OAP/mOCT-tk-CAT), or OAP/ AOCT (OAWAOCT-tk-CAT) driving CAT expression through a tk promoter were unable to be transactivated by Oct-2 in response to TPA and ionomycin treatment (Fig. 6 ). This result suggests that the AP-l-binding OAP element has weak enhancer activity in the absence of concomitant Oct-2 binding. The abrogation of OAP binding (mOAP/OCT-tk-CAT and AOAP/OCT-tk-CAT) also impaired the ability of the octamer motif to be transactivated by Oct-2 in response to TPA and ionomycin by "~90% (Fig. 6 B) . This result suggests that Oct-2 has very weak enhancer activity in response to TPA and ionomycin without concomitant AP-1 binding. Thus, both c/s-elements appear to require mutual cooperation for full enhancer properties. Of further interest is the observation that mutation or deletion of the OAP binding motif almost completely abrogated the ability to RA to antagonize the TPA/ionomycin-induced Oct-2-dependent activation of the IL-2 octamer binding site; this is probably due to the very low TPA/ionomycin-induced activation observed. Thus, RA inhibition was observed only when both OAP-and Oct-2-binding sites were allowed to synergize with each other.
PAR has been shown to antagonize the collagenase AP-1 enhancer activity in HeLa cells (18, 19) . Thus, a similar PAIL-AP-1 antagonism might occur at the IL-2-OAP motif in T cells. We therefore studied the effect of PA on the TPA/ionomycin-induced activation of five copies of the collagenase AP-1 c/s-element driving CAT transcription through the tk promoter. TREp2CAT activity compared with the wild-type receptor on the activity of OAP/OCT-tk-CAT in the presence of CMV-Oct-2 cotransfected into an tLA-resistant Jurkat subclone. Truncation of the NH2 terminus of the receptor did not affect the inhibitory activity on OAP/OCT-tk-CAT expression and only slightly decreased the RA-induced activation of TREp2-CAT reporter, carrying an RA-responsive element driving CAT gene transcription (Fig. 7) . In contrast, ddetion of the receptor DNA-binding domain significantly reduced both RA-mediated repression of the TPA/ionomycin-induced activation of OAP/OCT-tk-CAT and enhancement of TREp2-CAT expression (Fig. 7) . This suggests that direct DNA binding of RARa to the IL-2 sequences may be required for the effect on OAP/OCT c/s-regulatory function. To address this point further, we tested the ability of in vitro synthesized, or bacterially expressed, recombinant RARot to bind to the -96 to -66-bp OAP/OCT IL-2 sequences in addition to the RAREB. According to data previously reported (55, 56) , R A R a protein acquired RAREB DNA-binding activity after complementation with in vitro synthesized RXRo~: the presence of the receptor in the complex with RAREB was confirmed by use of an anti-RAR antibody (Fig.   8 C, left panel), lanes 4, 6, and not shown) . Interestingly, the complementation of RAR with nuclear extract from both untreated or TPA/ionomycin-activated Jurkat cells also conferred a distinct pattern of RAREfl DNA-binding activity, which was supershifted by the anti-KAR antibody (Fig. 8   C, left panel, lanes 9, 1I, and not shown) . This suggested that, in nuclear extracts, different cofactors were present that cooperate with receptor for DNA binding. In contrast, complementation with either R X R a or these different putative cofactors present in nuclear extract from both untreated or TPA/ionomycin-activated Jurkat cells was unable to confer the in vitro OAP/OCT motif DNA-binding ability to synthesized or bacterially expressed RARa proteins over a range of salt concentrations or DNA-binding incubation conditions (Fig. 8 C, right panel, lanes 5, 6, and not shown) . The OAP/OCT motif was only capable of forming a complex that included the Oct-1 factor present in nuclear extracts from either untreated or TPA/ionomycin activated cells, but not PAR, as confirmed by its insensitivity to anti-RAR antibody ( Fig. 8 C, right panel, lane 9 and not shown). In contrast, the addition of recombinant PARer inhibited the amount of the supershifted complex formed by OAP and Oct-1 nuclear factors and the OAP/OCT DNA motif (Fig. 8 D,  lanes 5-7) . The complex formed by nuclear Oct-1 alone and DNA was not affected by PARol (Fig. 8 D) . Mocktransformed bacterial lysate did not affect the formation of either complex (Fig. 8 D, lanes 2-4) .
Discussion
Jun and fos Participate in the OAP Octamer Complex and
Cooperate with Oct-2 for Transacting Function. We report here that Oct-2 is a very weak transactivator of the IL-2 octamer motif in the absence of phorbol ester and calcium ionophore, despite the presence of an active transcriptional activation domain. This would suggest a requirement for both PKC-and calcium-induced coregulatory signals in T cells. The requirement of coreguhtory signals for Oct-2 transcriptional activity has also been recently reported in B cells. These signals, which are specific for B cells and absent in HeLa cells, appear to be accounted for by the presence of OCA-B factors, which interact with Oct-2 (57) . Similar data have also been reported for E1A, which provides transcription activation function to Oct-4 via protein-protein interaction in embryonic stem cells (58) . Thus, transactivation properties of Oct-2 and Oct-4 appear to result from the ability of specific cell types to provide cooperating factors that give them functional competence. In addition to these recently identified coactivators, we report here that another of the cell-specific factors that can cooperate with Oct-2 is the AP-1 complex in T cells. We suggest also that the presence of the AP-1 factor underlies the requirement for extracellular regulatory signals (PKC and calcium ionophore) in Oct-2-mediated transactivation in T cells. In this respect, we have further characterized the previously described OAP 4~ complex, which binds to a region closely linked to the octamer motif in the IL-2 promoter (29) as containing an AP-1 complex. Our data confirm the recently reported presence ofjun in the OAP 4~ complex (30) .
In addition, we show the presence of immunoreactive fos protein(s) in the OAP 4~ complex. Furthermore, we show that overexpression of jun and fos proteins cooperate with Oct-2 for the transactivation of the IL-2 octamer motif, and that this cooperation is strictly required for full enhancer activity. The presence of an active transcriptional activation domain within Oct-2 suggests that the ability of AP-1 and other coregulatory factors to impart functional transcriptional competence to Oct-2 does not simply provide a transcriptional domain for a protein that lacks it, as in the case of VP16-Oct-1 interactions (13, 33) .
We have mapped a part of the TPA/calcium-induced transacting function of Oct-2 to the COOH terminus, a region rich in heptad leucine repeats with the potential to form a "leucine zipper"-like structure. It remains to be elucidated whether this region is capable if interacting with leudne zipper regions injun and fos proteins. We also observed differential transactivation of the OAP c/s-element by distinct members of thejun andfos family, withjun-B and Fos-B being the most active. The composition of the AP-1 factors cooperating with distinct transacting factors, such as Oct-1 and Oct-2, may therefore by influential in determining the transacting function of the final complex. This may explain the different transactivating function ofjun-B reported in this study compared with that described previously (30) . Such a selection for AP-1 complexes of different composition has previously been described for AP-1 cooperation with the nuclear factor of activated T cells (NFAT) motif of the IL-2 enhancer (59-61).
RARc~ Impairs the Oct-2-clependent AP-1/OAP Function.
Mapping of the Oct-2 domains required for TPA/calciuminduced activation function revealed that they overlapped the region required for negative regulation by RARoL. This suggests that a focus for both activator and inhibitor signals may occur on a unique pathway. We show here that this pathway could be represented by the AP-1 complex. Abrogation of AP-1 binding to the OAP c/s-element blunted the antagonistic activity of RAR. An indirect modulation of IL-2 promoter by PAR on AP-1/OAP function was suggested by the requirement for the receptor DNA-binding domain but not direct in vitro binding to the IL-2 octamer motif and by the ability of PAILct to inhibit the AP-1 binding activity to the IL-2-OAP/OCT sequence in vitro. A similar mechanism has been proposed for PAR antagonism of collagenase AP-1 cisdement by an inhibition of the AP-1 complex DNA-binding activity in HeLa cells independently from direct PAP, binding to DNA (18, 19, 62) . We used a similar model to demonstrate inhibition of TPA-induced activation of collagenase AP-1 c/s-regulatory activity by PARot in T cells. Therefore, although the in vivo binding of PAR to the OAP/OCT motif cannot be ruled out, the ability of the receptor to inhibit the OAP binding activity without direct DNA binding in vitro, presented here, is sufficient to suggest that PAR inhibits the functional synergism between AP-1 and Oct factors by preventing the binding ofjun andfis to the OAP binding site. An appropriate genetic context for AP-1 regulation seems to be required, as PA does not interfere with the activity of the AP-1 complex found in the NFAT element of IL-2 enhancer (23, 63) . Our data leave open, however, the question of the potential contribution of Oct factors in the negative regulation of AP-1 sites by RAR and their potential interaction with the receptor. In this respect, it should be noted that protein-protein interactions have been implicated in both the antagonism of Oct-2 function by glucocorticoid receptor (GIk; 64) and the synergism between GR and Oct-1 (65) . It is of further interest that the repression of the IL-2-OAP/ OCT motif by RA, described here, is not without similarity to a recent report describing PAR-mediated interference with the activation of the calcitonin/calcitonin gene-related peptide enhancer by cell-specific helix-loop-helix and octamer proteins in combination (66) . Another nuclear receptor (GR) has been described to cause a similar impairment of the functional cooperation between distinct c/s-elements (AP-1 and NFAT) in the IL-2 enhancer (21) .
Multiple Pathvays of AP-1 Regulation: Implications for T Cell Development. Octamer-binding proteins containing homeodomains are developmentally regulated and involved in the cascade of events controlling morphogenic processes (14) . As RA regulates octamer-binding proteins (9) (10) (11) (12) and IL-2 is active in T cell development (25, 26) , it is possible that PAR and octamer-binding factors might combine to modulate thymocyte differentiation through regulation of cytokine gene transcription. This hypothesis is consistent with our observation that PA can modulate T cell precursor development in an in vitro thymocyte differentiation system (67, 68) . To extend this hypothesis, the data described here and dsewhere (30, (59) (60) (61) 63 ) suggest a central role for AP-1 sites in the functional organization of the IL-2 enhancer, which is cornposed of several regulatory modules, including an AP-1 site that potentially cooperates with another closely linked transacting factor-binding motif. This site may well be responsible for differential regulation by external stimuli. The role of AP-1 in regulating Oct-2 and mediating RAR activity would strongly suggest that it may also contribute to the T cell differentiation process. Support for this comes from observations that changes in the AP-1 pathway accompany the induction of T cell tolerance (69) and thyrnocyte ontogeny (70) . As AP-1 responds to a broad range of activating stimuli, often unrelated to differentiation pathways, this transcription factor may provide signals that specify developmental programs on the basis of selective functional interactions with differentiation-related transacting factors.
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